Background: Metastatic breast cancer (MBC) treatment has changed substantially over time, but we do not know whether survival post-metastasis has improved at the population level. Methods: We searched for studies of MBC patients that reported survival after metastasis in at least two time periods between 1970 and the present. We used meta-regression models to test for survival improvement over time in four disease groups: recurrent, recurrent estrogen (ER)-positive, recurrent ER-negative, and de novo stage IV. We performed sensitivity analyses based on bias in some studies that could lead earlier cohorts to include more aggressive cancers. Results: There were 15 studies of recurrent MBC (N ¼ 18 678 patients; 3073 ER-positive and 1239 ER-negative); meta-regression showed no survival improvement among patients recurring between 1980 and 1990, but median survival increased from 21 (95% confidence interval [CI] ¼ 18 to 25) months to 38 (95% CI ¼ 31 to 47) months from 1990 to 2010. For ER-positive MBC patients, median survival increased during 1990-2010 from 32 (95% CI ¼ 23 to 43) to 57 (95% CI ¼ 37 to 87) months, and for ERnegative MBC patients from 14 (95% CI ¼ 11 to 19) to 33 (95% CI ¼ 21 to 51) months. Among eight studies (N ¼ 35 831) of de novo stage IV MBC, median survival increased during 1990-2010 from 20 (95% CI ¼ 16 to 24) to 31 (95% CI ¼ 24 to 39) months. Results did not change in sensitivity analyses. Conclusion: By bridging studies over time, we demonstrated improvements in survival for recurrent and de novo stage IV MBC overall and across ER-defined subtypes since 1990. These results can inform patient-doctor discussions about MBC prognosis and therapy.
Breast cancer is the leading cause of cancer death among women globally and the second leading cause in the United States (1, 2) . Treatment paradigms for this disease are changing rapidly and mortality is steadily declining, largely due to advances in population screening and early-stage treatments (3, 4) that decrease risk of distant recurrence. Women with metastatic breast cancer (MBC)-an estimated three-quarters of whom were diagnosed with stage I-III disease and later developed distant recurrence, and an estimated one-quarter of whom were diagnosed with de novo distant spread (stage IV) (5)-continue to have incurable disease. To treat MBC, there are 23 drugs that are recommended in the 2018 guidelines of the National Comprehensive Cancer Network or approved as of 2018 by the Food and Drug Administration (6) (7) (8) (9) . Most of these drugs demonstrated a survival benefit in randomized controlled trials (RCTs) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . However, in part because metastatic recurrence is not recorded in US population registries, we do not know whether RCT results have translated into improved survival at the population level for patients experiencing recurrence. Because new treatments are often toxic and costly, it is essential to assess the impact of these treatment changes on MBC survival for the average patient in the general population.
To assess the population-level impact of MBC treatment, several prior studies have examined the difference in survival between time periods ; in recurrent disease, the majority of these studies are within a single institution or network. However, no study has incorporated data across multiple decades and treatment settings, and studies have reached differing conclusions. Strikingly, because of these discrepancies, we do not currently know whether the changes made in the treatment of MBC have led to improved outcomes for patients.
To fill this important gap, we conducted meta-regression analyses of published results of changes in survival to examine trends over several decades and determine whether population-level survival after diagnosis of MBC has improved as new treatments were introduced. We also identified studies with biases that may obscure conclusions about populationbased survival trends and conducted sensitivity analyses excluding these studies. The results are intended to inform clinical practice and future data collection protocols to facilitate unbiased estimation of the population impact of MBC treatment advances.
Methods
This study used aggregate data from published studies and was exempt from Institutional Review Board approval.
Study Selection
Two investigators (JLC and AWK) searched for published, population-level studies of survival trends over time among patients with distant recurrence or de novo stage IV breast cancer ( Figure 1 ). For inclusion, studies had to fulfill the following criteria: 1) assessed overall or relative survival after metastasis for at least two distinct time intervals in a similar population; 2) time intervals reported covered some subset of the time period between 1970 and the present; and 3) reported median overall survival in months or 5-year overall or relative survival percentages, or provided a Kaplan-Meier curve. Only studies in English were included. We included only studies with at least two time intervals such that heterogeneity across time periods would be relatively reduced. We selected 1970 as the lower bound on the time period to study because all of the 23 drugs used today were introduced subsequent to 1970 (Figure 2 ). Multiple study types met our inclusion criteria: retrospective cohorts from single or multiple institutions, retrospective cohorts identified from cancer registries, and prospective cohorts of patients enrolled on successive RCTs from the same study group. Notably, we included RCT follow-up data from within the same institution or research network over time: in these reports, both arms of the RCT were included together, and the consistency of the institution or research network over time allowed for some between-timepoint internal consistency. We searched PubMed October 18, 2017 and again June 28, 2018 with the following terms: "population trends AND (metastatic breast cancer or advanced breast cancer or distant recurrence) AND overall survival." We augmented this search by reference tracking of identified articles, in particular of one landmark study of recurrent disease (25) and another of de novo stage IV disease (43), to find additional relevant studies.
Data Collection
Data extraction and review of inclusion and exclusion criteria were performed separately by two investigators (JLC and AWK). For each study, we extracted at least one of the following estimates for each cohort in given time interval: median overall survival (reported in days, months, or years), 5-year overall or relative survival percentages, or a Kaplan-Meier curve from which the aforementioned values could be inferred. We extracted the sample size of each time cohort and the starting and ending time of the interval defining the cohort. When available, we extracted the same information by estrogen receptor (ER) status. Where median overall survival was not reported, we converted the 5-year survival probability or Kaplan-Meier curve to the median overall survival time under the exponential distribution assumption. The assumption of exponential distribution for overall survival time was reasonable based on visual examination of the Kaplan-Meier curves.
In addition to this collection of data for meta-analysis, we categorized studies based on the types of metastatic disease included: only de novo stage IV disease, or at least 80% recurrent disease, with no more than 20% de novo stage IV disease ("primarily recurrent disease"). For studies of primarily recurrent disease, we categorized studies based on the types of recurrence included: at least 80% distant recurrence, with no more than 20% locoregional recurrence ("primarily distant recurrence"), or distant and locoregional recurrences, with greater than 20% locoregional recurrences. For studies of only recurrent or primarily recurrent disease, we noted whether there was a cap on year of diagnosis. We also noted for each study what prognostic factors (such as recurrence-free interval, ER positivity, age at diagnosis, and site of metastasis) were measured in different time intervals and whether they changed over time, and results of multivariable analysis, if performed.
Statistical Methods
We analyzed primarily recurrent disease, ER-positive primarily recurrent disease, ER-negative primarily recurrent disease, and de novo stage IV disease separately. There was only one study of de novo stage IV disease that included results by ER status separately. For each case, we performed random-effects metaregression analysis (46) assuming an underlying mixed effect model that predicted median overall survival based on the year of recurrence (Supplemental Methods, available online). We included a study-specific random effect to account for withinstudy correlations and weighted the analysis by the cohort size. We included a quadratic term of time in the regression to assess potential nonlinearity. The statistically significant quadratic terms (P ¼ .036 for recurrent disease, <.001 for ER-positive, .046 ER-negative, and .044 for de novo stage IV disease) suggested the inadequacy of the simple linear model for describing the time trend, and so these terms were retained. We tested for improvement over each decade (1980-1990, 1990-2000, and 2000-2010) by calculating the median survival ratio from the fitted function over that decade; reported P values are two-sided and those less than .05 were considered statistically significant.
For analysis of de novo stage IV disease, three studies reported 5-year relative survival rather than overall survival (40, 47, 48) , which we converted to median overall survival in months under the exponential distribution assumption. Relative survival in these studies was defined as the ratio of observed survival for people with stage IV breast cancer to expected survival for people from the reference population matched on demographic characteristics. Relative survival is expected to be close to overall survival in these instances, because the mortality of the reference population is almost negligible relative to the mortality of the stage IV cancer patients. To allow incorporation of the results of these three studies into the meta-analysis, we included an additional covariate indicating whether relative or overall survival was used, in order to adjust for a small but potential elevation in relative survival compared with overall survival.
We performed two sensitivity analyses in studies of primarily recurrent disease to explore the effects of study biases on our results. A subset of studies capped year of diagnosis either in the same year as, or shortly before, the year of recurrence, which could lead to overselection of aggressive disease in the earliest cohorts studied (Supplementary Figure 1 , available online). Another subset of studies included over 20% locoregional recurrences in their definition of metastatic recurrence. We repeated the meta-regression excluding each of these sets of studies in turn to assess impact on our results.
Results

Recurrent Breast Cancer
We identified 15 studies that included 18 678 breast cancer patients with primarily recurrent disease: these studies included analyses of overall survival trends in a series of adjuvant RCTs (N ¼ 2) (25,27) and metastatic RCTs (N ¼ 2) (34,37) conducted within a specific research network or institution over time; registry-based studies (N ¼ 3) (33, 35, 36) , and singleinstitution studies (N ¼ 8) (26, (28) (29) (30) (31) (32) 38, (49) (50) (51) (Table 1) . Individually, 12 of the 15 studies showed improvements in survival over time.
Meta (Table 2) .
We repeated this analysis for the eight studies (28) (29) (30) (31) (32) 35, 37, 49, 50) that collected data on unadjusted survival after recurrence separately for ER-positive (3073 patients) and ERnegative disease (1239 patients) (Table 2, Figure 3 , B and C). Although numbers were smaller than for recurrent disease as a whole, we observed similar trends in survival improvement over time in ER-positive and ER-negative recurrent disease: from 1980 to 1990, the median survival ratio was 1.08 (95% CI ¼ 0.66 to 1.79; P ¼ 0.75) for ER-positive disease and 0.95 (95% CI ¼ 0.55 to 1.66; P ¼ 0.87) for ER-negative disease; from 1990 to 2000, the median survival ratio was 1.25 (95% CI ¼ 1.05 to 1.49; P ¼ .014) for ER-positive disease and 1.30 (95% CI ¼ 1.08 to 1.57; P ¼ .007) for ER-negative disease; and from 2000 to 2010, the median survival ratio was 1.44 (95% CI ¼ 0.93 to 2.21; P ¼ .10) for ERpositive disease and 1.77 (95% CI ¼ 1.13 to 2.79; P ¼ .01) for ERnegative disease. We estimated median unadjusted survival in ER-positive disease to have been 29 Among the 12 studies that showed survival improvement over the interval studied, 10 included multivariable analysis incorporating variables associated with disease aggressiveness and survival after recurrence (Table 1 ). In 7 of these 10 multivariable analyses, the association between recurrence year and survival disappeared with adjustment for potential confounding variables related to disease aggressiveness (Table 1) . In other words, disease aggressiveness appeared to decrease over time, and this decrease appeared to explain much or all of the observed survival improvement. However, the variables associated with disease aggressiveness differed between studies (Supplementary Table 1 , available online). For example, 12 studies assessed ER status over time, with five showing an increase in ER-positive disease and seven showing no change. Similarly, nine studies assessed metastasis site: one showed a decrease in visceral disease, two showed an increase, and six showed no change. The most consistent change was an increase in recurrence-free interval, assessed in 13 studies and observed in 12 (Supplementary Table 1 Studies of time trends in survival with metastatic breast cancer included in meta-regression analysis primarily distant recurrence (N=15) and de novo stage IV (N=8) Figure 1 . Study selection.
Sensitivity Analyses to Account for Potential Study Biases
In eight studies, there was truncation of diagnosis ascertainment in the earliest cohorts of MBC patients with recurrent disease (hereafter called "left-truncation") that could introduce an ascertainment bias, where earlier cases would include more aggressive disease that was more likely to recur early (Supplementary Figure 1 , available online). In four studies, diagnosis and recurrence were truncated in the same year (25) (26) (27) (28) 30) , and in the other four, diagnosis was truncated 2-7 years before recurrence (29, 31, 33, 36 Figure 3A-C) , which are treated very differently from distant recurrences and have longer survival (55) . When we repeated the analysis without these five studies, we concluded there was no change in the finding that survival improved, though survival was modestly lower when only distant recurrences were included (vs distant and local recur- italic font indicates that a progression-free survival (but no overall survival) benefit was reported in a randomized clinical trial or meta-analysis; and plain font indicates that no overall survival benefit nor progression-free survival benefit has been reported. Year of introduction is date of Food and Drug Administration (FDA) approval or, for drugs that are not FDA approved to treat breast cancer (vinorelbine, liposomal doxorubicin, platinums), the date of the first major publication that led to widespread use. Dashed arrows show the transition of each therapy from the metastatic setting, where nearly all were originally introduced, to the early-stage setting. Figure 3D ). Only one of these studies reported survival separately for ER-positive and ER-negative disease (43) and showed improvement for ER-positive disease but not ERnegative disease from 1987 to 2000. Multivariable analysis was performed in four of the six studies: the association between time period of diagnosis and survival persisted after multivariable analysis in three of the four studies (Table 1) .
Discussion
This study examined population trends in overall survival of breast cancer patients with distant recurrence or de novo metastatic disease from studies spanning the 40-year interval from 1970 to 2010. We found no evidence for an improvement in survival between 1980 and 1990, consistent with the slow pace of new drug introduction in that time period. However, we found a substantial improvement beginning in 1990, consistent with the steady flow of new treatments that began with paclitaxel in 1992. The pattern and magnitude of survival improvement was similar between primarly recurrent and de novo stage IV disease and across ER-defined subtypes. Even for ER-negative disease, which has the worst prognosis, survival more than doubled between 1990 and 2010. These results support the impact of newer treatments on MBC survival at the population level and may inform patient-doctor discussions about the prognosis and treatment of MBC. We performed this study to address a gap in the data on survival of MBC patients in the general population. This gap exists in part because US population-based cancer registries do not continuously follow early-stage cancer patients for distant recurrence, which is how most breast cancer patients develop MBC (vs presenting with de novo stage IV disease). Thus, US registries cannot measure the interval between distant cancer recurrence and death. The studies we identified of MBC survival over time were heterogeneous in their time frames and patient populations. These between-study differences may account for their variable findings, with some concluding that there was a survival improvement over time and others not.
We note that some studies concluded that the survival improvement over time they observed was more likely to have resulted from a reduction in disease aggressiveness over time rather than from new treatments (27, 29) . This conclusion was based on the discrepancy between the univariate analyses, where a statistically significant association between calendar year and survival after recurrence was found, and the multivariable analyses including recurrence-free survival, where it often was not. We propose three possible explanations for why survival after recurrence would appear to improve over time and this association would disappear when adjusting for or stratifying by recurrence-free interval. The first is that, as proposed previously, disease aggressiveness has decreased over time. The second is that improved adjuvant therapy over time might lengthen recurrence-free interval and also survival after metastasis (eg, by selecting for more indolent micrometastases, which then would grow more slowly after recurrence). The third is that the same treatments used in the adjuvant setting, where they lengthen recurrence-free interval, are also used in the metastatic setting, where they independently lengthen survival after metastasis.
It appears unlikely that a reduction in disease aggressiveness over time would entirely explain our results of an improvement in survival over time. Notably, the surrogates for disease aggressiveness assessed in the different studies changed variably (or not at all) over time, whereas the lengthening of recurrence-free interval was nearly universal. This discordance suggests that the lengthening of the recurrence-free interval may have occurred in these studies because of factors other than those captured by the markers of disease aggressiveness. In particular, recurrence-free interval may have lengthened because of improved adjuvant therapy and/or biased ascertainment in studies that lefttruncated ascertainment of the earliest cohorts, such that the limited time-window between diagnosis and recurrence would select for shorter survival in earlier years. We addressed this bias in two ways. First, because the years of the earliest time period (the one most sensitive to this bias) varied between studies, we mitigated bias by including all studies together in a metaregression. Second, we performed a sensitivity analysis excluding studies with this ascertainment bias, which did not change the finding of survival improvement over time. Furthermore, we observed survival improvement in both ER-positive and ER-negative MBC, and thus the survival improvement over time cannot be fully explained by a potential increase in the prevalence of ERpositive relative to ER-negative disease (57) .
It also appears unlikely that improved adjuvant therapy would account entirely for the improvement in survival after distant recurrence seen here, given that we find a remarkably similar improvement in survival after metastasis in de novo stage IV disease, where no adjuvant therapy is given. Previous studies have hypothesized the reverse, that the administration of adjuvant therapy prior to recurrence might decrease survival after metastasis by selecting for resistant clones (58). We do not see shorter survival after primarily distant recurrence compared with de novo stage IV disease, but we also do not see longer survival as might have been expected if adjuvant therapy selected for more indolent recurrent disease.
We suspect that the most likely explanation for the disappearance of the effect of year of recurrence on survival after recurrence after adjusting for or stratifying by recurrence-free interval is that successful treatments for metastatic disease are often shifted to earlier-stage breast cancer. In other words, the accelerated pace of new drug development after 1990 may have improved both recurrence-free interval and survival with metastatic disease in the same patients. For example, HER2-targeted therapies offer a longer recurrence-free interval and also longer survival after recurrence (18, 59) , and other drug classes including endocrine therapy and chemotherapy may function similarly. Thus, adjustment for recurrence-free interval could obscure a true effect of improved treatment on survival after recurrence because the advances that explain improved recurrence-free interval could also explain improved survival after recurrence.
We note that there have been other changes in the diagnosis and management of breast cancer over time that could lead to changes in recurrence-free interval or survival after recurrence, independent of the effects of improvements in treatment. Earlier detection of distant recurrence [eg, by more use of advanced imaging after primary treatment (60) ] over time could cause lead-time bias resulting in longer survival, but this change should also lead to shorter recurrence-free interval, which was not observed. Conversely, increased population screening (eg, mammography) for early-stage disease over time could cause lead-time bias resulting in longer recurrence-free interval, but likely unchanged survival. It is difficult to estimate how these effects in concert might lead to changes on the population level, but improvements in treatment remains the simplest explanation to account for lengthening of recurrence-free survival, lengthening of survival after recurrence, and the interdependence of these two time intervals.
Our study has limitations. First, only three of the studies we analyzed reported data on HER2 status, so we cannot determine how much the success of HER2-targeted therapies may have contributed to our findings for ER-positive and ER-negative breast cancer. However, because HER2-positive cancers were the minority in studies that reported HER2 (<30%) (28, 50, 61) , they are unlikely to account for all of the observed survival improvement, suggesting that improvement has been made in triple-negative disease as well. Similarly, only one-quarter of the patients analyzed for recurrent disease had ER status available, decreasing the precision of estimates by ER status. Second, we are unable to link improvement in survival to the introduction of specific therapies, instead focusing on decade-by-decade trends; going forward, data sets that allow more granular estimates of survival after metastasis (by year instead of interval of diagnosis) and include subtype information (ER and HER2 status and, as therapies are increasingly targeted, other factors such as BRCA1/2 status) will be essential to evaluate the impact of specific therapies on survival. Third, we cannot rule out that a shift in disease biology contributed to our findings. Changes in practice beyond new treatments, such as earlier diagnosis of metastatic recurrence due to more sensitive imaging modalities, may also have contributed to observed survival trends. Fourth, we may have missed certain reports with our search strategy, such as those not in English. Publication bias might have biased our studies toward those showing an improvement; the result that survival did not improve over time would be provocative with adequate power (27) , but smaller studies not showing an improvement may not have pursued publication. Fifth, although we collected studies across the entire period from 1970 to 2018, data were too sparse between 1970 and 1980 and between 2010 and 2018 to inform estimates. Further studies will be needed to assess additional improvement after 2010, in particular of newer therapies such as the CDK4/6 inhibitors, where no overall survival benefit has been seen yet in randomized clinical trials. Finally, the existing evidence comes from a subset of the population, because some of the studies came from single institutions (albeit different ones).
There are several implications of our results for filling data gaps and biases in determining true population trends in MBC survival. The ascertainment bias we identified with lefttruncated data could be resolved by including any distant recurrence, without a cap on diagnosis year. Although costly, the most straightforward way to bridge the data gap in collection of recurrence information by US population-based cancer registries would be to mandate reporting of distant recurrence. Alternative indirect approaches have been developed such as linkage of registry information to claims data in SEER-Medicare and other settings, with some success but also limitations (62) (63) (64) (65) (66) (67) (68) . Promising new approaches include a broader data linkage initiative encompassing pharmacy, pathology, imaging, electronic medical records and other data sources, and using natural language processing or other methods to capture events (69) (70) (71) (72) (73) (74) . Simulation models may also help to fill the evidence gap by simulating cancer outcomes by incorporating the best available data and testing assumptions through sensitivity analyses (3, 75) .
The question of whether MBC patients are living longer with newer treatments is clinically relevant. Systemic therapies, including novel targeted agents, have clinically significant side effects and costs that must be weighed against their potential benefits. Evidence of progress can inform patient-doctor conversations about MBC prognosis and the likely benefit of existing therapies.
In conclusion, our meta-regression of existing studies demonstrated an improvement in survival over time for MBC, whether recurrent or de novo and across ER subtypes. This study synthesized evidence across a 40-year horizon and supported the hypothesis that advances tested in RCTs have translated to improved survival in the population. The gaps and biases we identified offer a road map for improvement in observational data collection to support future measurement of the real-world benefit of emerging therapies that show promise in RCTs.
